Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$48.01 - $173.25
Next Earnings Date
May 06 2025
Next Earnings Date
May 06 2025
Latest price
Market Cap | $5.77B |
EV | $5.76B |
Shares Outstanding | 97.03M |
Beta | 0.92 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $147.33 |
P/E 2025E | 9.32x |
P/Revenue 2025E | 1.89x |
Revenue | 39.40% |
EPS | - |
Operating Cash Flow | 22.60% |
Free Cash Flow | 10.70% |
Revenue | 28.60% |
EPS | 79.60% |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 81.06% |
Net Profit Margin 2025E | 16.75% |
ROE 2025E | 25.09% |
ROCE 2024 | 19.71% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Sarepta Therapeutics, Inc.
SRPT
Sector
Healthcare
Industry
Biotechnology
CEO
Ingram, Douglas
Employees
1,372
Website
www.sarepta.comIPO Date
1997-06-04
Headquarters
215 First Street, Suite 415, Cambridge, Massachusetts, 02142, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved